N NUVALENT INC
$105.43
| Market Cap | $8.29B |
| P/E Ratio | — |
| Forward P/E | -26.13 |
| Dividend Yield | — |
| Beta | 1.31 |
| 52W Range | $59.32 - $111.99 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $639.00K | 6,359 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 257 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Balcom AlexandraChief Financial Officer | Sale | 2,469 | $106.18 | $262.16K | 01 Apr 2026 | 01 Apr 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 5,417 | $105.30 | $570.41K | 01 Apr 2026 | 01 Apr 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 3,544 | $104.39 | $369.96K | 01 Apr 2026 | 01 Apr 2026 |
| Darlene NociChief Development Officer | Sale | 2,968 | $98.13 | $291.25K | 30 Mar 2026 | 01 Apr 2026 |
| Darlene NociChief Development Officer | Sale | 2,532 | $97.43 | $246.69K | 30 Mar 2026 | 01 Apr 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 2,803 | $99.46 | $278.79K | 26 Mar 2026 | 30 Mar 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 1,757 | $98.21 | $172.55K | 26 Mar 2026 | 30 Mar 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 940 | $97.50 | $91.65K | 26 Mar 2026 | 30 Mar 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 13,700 | $100.16 | $1.37M | 25 Mar 2026 | 24 Mar 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 1,160 | $96.50 | $111.94K | 24 Mar 2026 | 24 Mar 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 7,671 | $95.88 | $735.50K | 24 Mar 2026 | 24 Mar 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 2,599 | $95.03 | $246.98K | 24 Mar 2026 | 24 Mar 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 1,703 | $99.71 | $169.81K | 13 Mar 2026 | 12 Mar 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 2,597 | $98.83 | $256.66K | 13 Mar 2026 | 12 Mar 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 804 | $97.89 | $78.70K | 13 Mar 2026 | 12 Mar 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 306 | $99.12 | $30.33K | 12 Mar 2026 | 12 Mar 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 5,505 | $98.44 | $541.91K | 12 Mar 2026 | 12 Mar 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 24,189 | $97.79 | $2.37M | 12 Mar 2026 | 12 Mar 2026 |
| Porter James RichardPresident and CEO | Sale | 400 | $100.19 | $40.08K | 06 Mar 2026 | 06 Mar 2026 |
| Porter James RichardPresident and CEO | Sale | 16,015 | $99.29 | $1.59M | 06 Mar 2026 | 06 Mar 2026 |
| Porter James RichardPresident and CEO | Sale | 13,585 | $98.59 | $1.34M | 06 Mar 2026 | 06 Mar 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 200 | $103.96 | $20.79K | 26 Feb 2026 | 02 Mar 2026 |
| Noci DarleneChief Development Officer | Sale | 200 | $104.25 | $20.85K | 26 Feb 2026 | 02 Mar 2026 |
| Noci DarleneChief Development Officer | Sale | 2,300 | $103.44 | $237.91K | 26 Feb 2026 | 02 Mar 2026 |
| Noci DarleneChief Development Officer | Sale | 3,000 | $102.64 | $307.92K | 26 Feb 2026 | 02 Mar 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 2,602 | $103.41 | $269.07K | 26 Feb 2026 | 02 Mar 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 2,698 | $102.64 | $276.92K | 26 Feb 2026 | 02 Mar 2026 |
| Noci DarleneChief Development Officer | Sale | 63 | $103.39 | $6.51K | 29 Jan 2026 | 02 Feb 2026 |
| Noci DarleneChief Development Officer | Sale | 3,429 | $101.80 | $349.07K | 29 Jan 2026 | 02 Feb 2026 |
| Noci DarleneChief Development Officer | Sale | 1,819 | $102.67 | $186.76K | 29 Jan 2026 | 02 Feb 2026 |
| Noci DarleneChief Development Officer | Sale | 189 | $100.95 | $19.08K | 29 Jan 2026 | 02 Feb 2026 |
| Darlene NociChief Development Officer | Sale | 1,819 | $102.67 | $186.76K | 29 Jan 2026 | 02 Feb 2026 |
| Darlene NociChief Development Officer | Sale | 189 | $100.95 | $19.08K | 29 Jan 2026 | 02 Feb 2026 |
| Darlene NociChief Development Officer | Sale | 63 | $103.39 | $6.51K | 29 Jan 2026 | 02 Feb 2026 |
| Darlene NociChief Development Officer | Sale | 3,429 | $101.80 | $349.07K | 29 Jan 2026 | 02 Feb 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 14,300 | $110.16 | $1.58M | 22 Jan 2026 | 23 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 700 | $109.84 | $76.89K | 21 Jan 2026 | 23 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 675 | $98.40 | $66.42K | 06 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 1,331 | $97.33 | $129.55K | 06 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 225 | $98.40 | $22.14K | 06 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 1,321 | $96.75 | $127.81K | 06 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 225 | $98.40 | $22.14K | 06 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 225 | $98.40 | $22.14K | 06 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 1,635 | $97.33 | $159.13K | 06 Jan 2026 | 07 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 4,905 | $97.33 | $477.40K | 06 Jan 2026 | 07 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 3,963 | $96.75 | $383.42K | 06 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 183 | $98.40 | $18.01K | 06 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 1,075 | $96.75 | $104.01K | 06 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 189 | $98.40 | $18.60K | 06 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 1,369 | $97.33 | $133.24K | 06 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 1,106 | $96.75 | $107.01K | 06 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 1,635 | $97.33 | $159.13K | 06 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 1,635 | $97.33 | $159.13K | 06 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 1,321 | $96.75 | $127.81K | 06 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 1,321 | $96.75 | $127.81K | 06 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 225 | $98.40 | $22.14K | 06 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 675 | $98.40 | $66.42K | 06 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 4,905 | $97.33 | $477.40K | 06 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 189 | $98.40 | $18.60K | 06 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 1,106 | $96.75 | $107.01K | 06 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 1,369 | $97.33 | $133.24K | 06 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 225 | $98.40 | $22.14K | 06 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 1,321 | $96.75 | $127.81K | 06 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 183 | $98.40 | $18.01K | 06 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 1,635 | $97.33 | $159.13K | 06 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 1,321 | $96.75 | $127.81K | 06 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 225 | $98.40 | $22.14K | 06 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 1,321 | $96.75 | $127.81K | 06 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 3,963 | $96.75 | $383.42K | 06 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 1,635 | $97.33 | $159.13K | 06 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 1,331 | $97.33 | $129.55K | 06 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 1,075 | $96.75 | $104.01K | 06 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 1,635 | $97.33 | $159.13K | 06 Jan 2026 | 07 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 1,337 | $98.52 | $131.72K | 05 Jan 2026 | 07 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 8,147 | $97.96 | $798.08K | 05 Jan 2026 | 07 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 3,679 | $96.06 | $353.40K | 05 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 326 | $98.52 | $32.12K | 05 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 897 | $96.06 | $86.17K | 05 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 1,137 | $97.96 | $111.38K | 05 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 660 | $96.85 | $63.92K | 05 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 513 | $96.06 | $49.28K | 05 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 317 | $98.52 | $31.23K | 05 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 1,119 | $96.85 | $108.38K | 05 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 871 | $96.06 | $83.67K | 05 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 1,119 | $96.85 | $108.38K | 05 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 871 | $96.06 | $83.67K | 05 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 1,929 | $97.96 | $188.96K | 05 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 1,119 | $96.85 | $108.38K | 05 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 871 | $96.06 | $83.67K | 05 Jan 2026 | 07 Jan 2026 |
| Porter James RichardPresident and CEO | Sale | 4,727 | $96.85 | $457.81K | 05 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 1,987 | $97.96 | $194.65K | 05 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 1,153 | $96.85 | $111.67K | 05 Jan 2026 | 07 Jan 2026 |
| Pelish Henry E.Chief Scientific Officer | Sale | 186 | $98.52 | $18.32K | 05 Jan 2026 | 07 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 1,929 | $97.96 | $188.96K | 05 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 317 | $98.52 | $31.23K | 05 Jan 2026 | 07 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 1,929 | $97.96 | $188.96K | 05 Jan 2026 | 07 Jan 2026 |
| Turner Christopher DurantChief Medical Officer | Sale | 317 | $98.52 | $31.23K | 05 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 1,119 | $96.85 | $108.38K | 05 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 1,337 | $98.52 | $131.72K | 05 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 8,147 | $97.96 | $798.08K | 05 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 1,137 | $97.96 | $111.38K | 05 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 186 | $98.52 | $18.32K | 05 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 660 | $96.85 | $63.92K | 05 Jan 2026 | 07 Jan 2026 |
| Henry E. PelishChief Scientific Officer | Sale | 513 | $96.06 | $49.28K | 05 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 871 | $96.06 | $83.67K | 05 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 326 | $98.52 | $32.12K | 05 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 1,987 | $97.96 | $194.65K | 05 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 317 | $98.52 | $31.23K | 05 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 1,929 | $97.96 | $188.96K | 05 Jan 2026 | 07 Jan 2026 |
| Christopher Durant TurnerChief Medical Officer | Sale | 871 | $96.06 | $83.67K | 05 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 317 | $98.52 | $31.23K | 05 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 4,727 | $96.85 | $457.81K | 05 Jan 2026 | 07 Jan 2026 |
| James Richard PorterPresident and CEO | Sale | 3,679 | $96.06 | $353.40K | 05 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 317 | $98.52 | $31.23K | 05 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 1,929 | $97.96 | $188.96K | 05 Jan 2026 | 07 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 1,119 | $96.85 | $108.38K | 05 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 1,153 | $96.85 | $111.67K | 05 Jan 2026 | 07 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 897 | $96.06 | $86.17K | 05 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 1,929 | $97.96 | $188.96K | 05 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 1,119 | $96.85 | $108.38K | 05 Jan 2026 | 07 Jan 2026 |
| Alexandra BalcomChief Financial Officer | Sale | 871 | $96.06 | $83.67K | 05 Jan 2026 | 07 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 5,455 | $100.77 | $549.70K | 02 Jan 2026 | 05 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 4,005 | $100.03 | $400.62K | 02 Jan 2026 | 05 Jan 2026 |
| Miller Deborah AnnChief Legal Officer | Sale | 540 | $101.47 | $54.79K | 02 Jan 2026 | 05 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 540 | $101.47 | $54.79K | 02 Jan 2026 | 05 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 5,455 | $100.77 | $549.70K | 02 Jan 2026 | 05 Jan 2026 |
| Deborah Ann MillerChief Legal Officer | Sale | 4,005 | $100.03 | $400.62K | 02 Jan 2026 | 05 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 642 | $101.22 | $64.98K | 30 Dec 2025 | 02 Jan 2026 |
| Noci DarleneChief Development Officer | Sale | 3,358 | $99.82 | $335.20K | 30 Dec 2025 | 02 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 3,358 | $99.82 | $335.20K | 30 Dec 2025 | 02 Jan 2026 |
| Darlene NociChief Development Officer | Sale | 642 | $101.22 | $64.98K | 30 Dec 2025 | 02 Jan 2026 |
| Balcom AlexandraChief Financial Officer | Sale | 100 | $111.32 | $11.13K | 08 Dec 2025 | 10 Dec 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 6,984 | $110.31 | $770.41K | 08 Dec 2025 | 10 Dec 2025 |
| Noci DarleneChief Development Officer | Sale | 3,355 | $108.72 | $364.76K | 28 Nov 2025 | 02 Dec 2025 |
| Noci DarleneChief Development Officer | Sale | 645 | $107.85 | $69.56K | 28 Nov 2025 | 02 Dec 2025 |
| Darlene NociChief Development Officer | Sale | 3,355 | $108.72 | $364.76K | 28 Nov 2025 | 02 Dec 2025 |
| Darlene NociChief Development Officer | Sale | 645 | $107.85 | $69.56K | 28 Nov 2025 | 02 Dec 2025 |
| Shair Matthew | Sale | 1,193 | $110.42 | $131.73K | 24 Nov 2025 | 26 Nov 2025 |
| Shair Matthew | Sale | 572 | $109.77 | $62.79K | 24 Nov 2025 | 26 Nov 2025 |
| Shair Matthew | Sale | 2,026 | $109.77 | $222.39K | 24 Nov 2025 | 26 Nov 2025 |
| Shair Matthew | Sale | 638 | $108.73 | $69.37K | 24 Nov 2025 | 26 Nov 2025 |
| Flynn James E | Sale | 371,287 | $95.45 | $35.44M | 24 Nov 2025 | 24 Nov 2025 |
| Shair Matthew | Sale | 336 | $110.42 | $37.10K | 24 Nov 2025 | 26 Nov 2025 |
| Shair Matthew | Sale | 2,262 | $108.73 | $245.95K | 24 Nov 2025 | 26 Nov 2025 |
| Shair Matthew | Sale | 104 | $107.70 | $11.20K | 24 Nov 2025 | 26 Nov 2025 |
| Shair Matthew | Sale | 369 | $107.70 | $39.74K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 336 | $110.42 | $37.10K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 1,193 | $110.42 | $131.73K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 572 | $109.77 | $62.79K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 2,026 | $109.77 | $222.39K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 638 | $108.73 | $69.37K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 369 | $107.70 | $39.74K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 2,262 | $108.73 | $245.95K | 24 Nov 2025 | 26 Nov 2025 |
| Matthew ShairDirector | Sale | 104 | $107.70 | $11.20K | 24 Nov 2025 | 26 Nov 2025 |
| James E FlynnDirector, 10% Owner/ Director, 10% Owner/ Director, 10% Owner/ Director, 10% Owner/ Director, 10% Owner/ Director, 10% Owner/ Director, 10% Owner/ Director, 10% Owner | Sale | 371,287 | $95.45 | $35.44M | 24 Nov 2025 | 24 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 509 | $104.54 | $53.21K | 18 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 220 | $103.61 | $22.79K | 18 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 509 | $104.54 | $53.21K | 18 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 220 | $103.61 | $22.79K | 18 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 380 | $103.68 | $39.40K | 17 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 5,055 | $103.27 | $522.03K | 17 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 3,194 | $102.13 | $326.20K | 17 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 4,496 | $100.58 | $452.21K | 17 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 3,609 | $93.80 | $338.52K | 17 Nov 2025 | 19 Nov 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 608 | $107.04 | $65.08K | 17 Nov 2025 | 19 Nov 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 8,517 | $105.98 | $902.63K | 17 Nov 2025 | 19 Nov 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 15,075 | $105.16 | $1.59M | 17 Nov 2025 | 19 Nov 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 3,266 | $95.12 | $310.66K | 17 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 380 | $103.68 | $39.40K | 17 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 4,496 | $100.58 | $452.21K | 17 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 3,609 | $93.80 | $338.52K | 17 Nov 2025 | 19 Nov 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 608 | $107.04 | $65.08K | 17 Nov 2025 | 19 Nov 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 8,517 | $105.98 | $902.63K | 17 Nov 2025 | 19 Nov 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 15,075 | $105.16 | $1.59M | 17 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 5,055 | $103.27 | $522.03K | 17 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 3,194 | $102.13 | $326.20K | 17 Nov 2025 | 19 Nov 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 3,266 | $95.12 | $310.66K | 17 Nov 2025 | 19 Nov 2025 |
| Noci DarleneChief Development Officer | Sale | 218 | $104.58 | $22.80K | 30 Oct 2025 | 31 Oct 2025 |
| Noci DarleneChief Development Officer | Sale | 1,091 | $103.09 | $112.47K | 30 Oct 2025 | 31 Oct 2025 |
| Noci DarleneChief Development Officer | Sale | 350 | $100.69 | $35.24K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 9,382 | $104.78 | $983.05K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 3,491 | $103.90 | $362.71K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 600 | $100.96 | $60.58K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 500 | $99.66 | $49.83K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 1,273 | $97.98 | $124.73K | 30 Oct 2025 | 31 Oct 2025 |
| Noci DarleneChief Development Officer | Sale | 1,114 | $104.21 | $116.09K | 30 Oct 2025 | 31 Oct 2025 |
| Noci DarleneChief Development Officer | Sale | 1,170 | $102.07 | $119.42K | 30 Oct 2025 | 31 Oct 2025 |
| Noci DarleneChief Development Officer | Sale | 57 | $98.91 | $5.64K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 3,733 | $102.88 | $384.05K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 2,121 | $102.00 | $216.34K | 30 Oct 2025 | 31 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 700 | $96.65 | $67.66K | 30 Oct 2025 | 31 Oct 2025 |
| Darlene NociChief Development Officer | Sale | 1,091 | $103.09 | $112.47K | 30 Oct 2025 | 31 Oct 2025 |
| Darlene NociChief Development Officer | Sale | 350 | $100.69 | $35.24K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 9,382 | $104.78 | $983.05K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 3,491 | $103.90 | $362.71K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 600 | $100.96 | $60.58K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 1,273 | $97.98 | $124.73K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 700 | $96.65 | $67.66K | 30 Oct 2025 | 31 Oct 2025 |
| Darlene NociChief Development Officer | Sale | 218 | $104.58 | $22.80K | 30 Oct 2025 | 31 Oct 2025 |
| Darlene NociChief Development Officer | Sale | 1,114 | $104.21 | $116.09K | 30 Oct 2025 | 31 Oct 2025 |
| Darlene NociChief Development Officer | Sale | 1,170 | $102.07 | $119.42K | 30 Oct 2025 | 31 Oct 2025 |
| Darlene NociChief Development Officer | Sale | 57 | $98.91 | $5.64K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 3,733 | $102.88 | $384.05K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 2,121 | $102.00 | $216.34K | 30 Oct 2025 | 31 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 500 | $99.66 | $49.83K | 30 Oct 2025 | 31 Oct 2025 |
| Shair Matthew | Sale | 9,154 | $100.27 | $917.87K | 28 Oct 2025 | 29 Oct 2025 |
| Shair Matthew | Sale | 32,455 | $100.27 | $3.25M | 28 Oct 2025 | 29 Oct 2025 |
| Matthew ShairDirector | Sale | 32,455 | $100.27 | $3.25M | 28 Oct 2025 | 29 Oct 2025 |
| Matthew ShairDirector | Sale | 9,154 | $100.27 | $917.87K | 28 Oct 2025 | 29 Oct 2025 |
| Shair Matthew | Sale | 4,046 | $100.23 | $405.53K | 27 Oct 2025 | 29 Oct 2025 |
| Shair Matthew | Sale | 14,345 | $100.23 | $1.44M | 27 Oct 2025 | 29 Oct 2025 |
| Matthew ShairDirector | Sale | 4,046 | $100.23 | $405.53K | 27 Oct 2025 | 29 Oct 2025 |
| Matthew ShairDirector | Sale | 14,345 | $100.23 | $1.44M | 27 Oct 2025 | 29 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 5,000 | $94.91 | $474.55K | 20 Oct 2025 | 22 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 5,000 | $94.91 | $474.55K | 20 Oct 2025 | 22 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 4,900 | $92.50 | $453.25K | 16 Oct 2025 | 17 Oct 2025 |
| Porter James RichardPresident and CEO | Sale | 700 | $92.63 | $64.84K | 16 Oct 2025 | 17 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 5,199 | $91.37 | $475.03K | 16 Oct 2025 | 17 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 2,277 | $90.54 | $206.16K | 16 Oct 2025 | 17 Oct 2025 |
| Porter James RichardPresident and CEO | Sale | 1,114 | $92.19 | $102.70K | 16 Oct 2025 | 17 Oct 2025 |
| Porter James RichardPresident and CEO | Sale | 13,876 | $90.91 | $1.26M | 16 Oct 2025 | 17 Oct 2025 |
| Porter James RichardPresident and CEO | Sale | 11,310 | $90.01 | $1.02M | 16 Oct 2025 | 17 Oct 2025 |
| James Richard PorterPresident and CEO | Sale | 700 | $92.63 | $64.84K | 16 Oct 2025 | 17 Oct 2025 |
| James Richard PorterPresident and CEO | Sale | 13,876 | $90.91 | $1.26M | 16 Oct 2025 | 17 Oct 2025 |
| James Richard PorterPresident and CEO | Sale | 11,310 | $90.01 | $1.02M | 16 Oct 2025 | 17 Oct 2025 |
| James Richard PorterPresident and CEO | Sale | 1,114 | $92.19 | $102.70K | 16 Oct 2025 | 17 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 5,199 | $91.37 | $475.03K | 16 Oct 2025 | 17 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 2,277 | $90.54 | $206.16K | 16 Oct 2025 | 17 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 4,900 | $92.50 | $453.25K | 16 Oct 2025 | 17 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 1,683 | $85.57 | $144.01K | 15 Oct 2025 | 17 Oct 2025 |
| Miller Deborah AnnChief Legal Officer | Sale | 15,624 | $89.98 | $1.41M | 15 Oct 2025 | 17 Oct 2025 |
| Pelish Henry E.Chief Scientific Officer | Sale | 14,205 | $90.04 | $1.28M | 15 Oct 2025 | 17 Oct 2025 |
| Deborah Ann MillerChief Legal Officer | Sale | 15,624 | $89.98 | $1.41M | 15 Oct 2025 | 17 Oct 2025 |
| Henry E. PelishChief Scientific Officer | Sale | 14,205 | $90.04 | $1.28M | 15 Oct 2025 | 17 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 1,683 | $85.57 | $144.01K | 15 Oct 2025 | 17 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 1,700 | $87.67 | $149.04K | 14 Oct 2025 | 15 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 5,820 | $86.63 | $504.19K | 14 Oct 2025 | 15 Oct 2025 |
| Pelish Henry E.Chief Scientific Officer | Sale | 400 | $87.39 | $34.96K | 14 Oct 2025 | 15 Oct 2025 |
| Pelish Henry E.Chief Scientific Officer | Sale | 1,167 | $84.98 | $99.17K | 14 Oct 2025 | 15 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 200 | $88.90 | $17.78K | 14 Oct 2025 | 15 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 12,280 | $85.75 | $1.05M | 14 Oct 2025 | 15 Oct 2025 |
| Pelish Henry E.Chief Scientific Officer | Sale | 866 | $86.11 | $74.57K | 14 Oct 2025 | 15 Oct 2025 |
| Henry E. PelishChief Scientific Officer | Sale | 400 | $87.39 | $34.96K | 14 Oct 2025 | 15 Oct 2025 |
| Henry E. PelishChief Scientific Officer | Sale | 866 | $86.11 | $74.57K | 14 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 200 | $88.90 | $17.78K | 14 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 5,820 | $86.63 | $504.19K | 14 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 12,280 | $85.75 | $1.05M | 14 Oct 2025 | 15 Oct 2025 |
| Henry E. PelishChief Scientific Officer | Sale | 1,167 | $84.98 | $99.17K | 14 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 1,700 | $87.67 | $149.04K | 14 Oct 2025 | 15 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 1,596 | $89.22 | $142.40K | 13 Oct 2025 | 15 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 6,138 | $87.90 | $539.53K | 13 Oct 2025 | 15 Oct 2025 |
| Pelish Henry E.Chief Scientific Officer | Sale | 7,637 | $89.81 | $685.88K | 13 Oct 2025 | 15 Oct 2025 |
| Balcom AlexandraChief Financial Officer | Sale | 12,266 | $88.73 | $1.09M | 13 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 6,138 | $87.90 | $539.53K | 13 Oct 2025 | 15 Oct 2025 |
| Henry E. PelishChief Scientific Officer | Sale | 7,637 | $89.81 | $685.88K | 13 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 1,596 | $89.22 | $142.40K | 13 Oct 2025 | 15 Oct 2025 |
| Alexandra BalcomChief Financial Officer | Sale | 12,266 | $88.73 | $1.09M | 13 Oct 2025 | 15 Oct 2025 |
Frequently Asked Questions
What is NUVL stock price today?
NUVALENT INC (NUVL) is currently trading at $105.43. The stock has a 52-week range of $59.32 to $111.99 and a market capitalization of $8.29B.
Is NUVL a good stock to buy in 2026?
NUVALENT INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +54.3%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling NUVL stock?
There have been 257 insider transactions for NUVL in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has NUVL stock performed over the past year?
NUVALENT INC (NUVL) has returned +54.3% over the past 12 months. The stock traded between $59.32 and $111.99 during this period, and is currently at $105.43.
Which hedge funds own NUVL (NUVALENT INC)?
1 tracked hedge funds currently hold NUVL in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is NUVL's market cap and valuation?
NUVALENT INC (NUVL) has a market capitalization of $8.29B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is NUVL's revenue and profitability?
NUVALENT INC reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of 1.31.
What sector is NUVL in and who are its biggest institutional holders?
NUVALENT INC (NUVL) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.